AbSci: AI-Based Antibody Development Meets Billion-Dollar Hair Loss Market - H.C. Wainwright Sees 74% Upside Potential
Reading Time: 3 minutes
Looking at the top price targets set by analysts, on August 12, AbSci Corp. (ABSI) stands out positively after a confirmed buy recommendation from H.C. Wainwright with a price target of 16 USD. Generative Artificial Intelligence as a Driver of Drug Development AbSci Corp. utilizes its proprietary ATLAS AI platform to develop biological drugs and antibodies from scratch. This so-called de novo development aims to accelerate entry into markets with a volume of several billion USD. In August 2026, the biotech company announced a major milestone:...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
